Analysts Offer Insights on Healthcare Companies: Vertex Pharm. (NASDAQ: VRTX), Nivalis Therapeutics (NASDAQ: NVLS) and Seattle Genetics (NASDAQ: SGEN)

By Carrie Williams

Analysts fell to the sidelines weighing in on Vertex Pharm. (NASDAQ: VRTX), Nivalis Therapeutics (NASDAQ: NVLS) and Seattle Genetics (NASDAQ: SGEN) with neutral ratings,indicating that the experts are neither bullish nor bearish on the stocks.

Vertex Pharm. (NASDAQ: VRTX)

Barclays analyst Geoff Meacham downgraded Vertex Pharm. (NASDAQ: VRTX) to Hold today. The company’s shares closed yesterday at $86.90.

According to TipRanks.com, Meacham is a 5-star analyst with an average return of 15.1% and a 60.5% success rate. Meacham covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Achillion Pharmaceuticals, and Merrimack Pharmaceuticals.

Currently, the analyst consensus on Vertex Pharm. is Moderate Buy and the average price target is $101.75, representing a 17.1% upside.

In a report issued on November 18, Janney Montgomery also initiated coverage with a Hold rating on the stock with a $98 price target.
Nivalis Therapeutics (NASDAQ: NVLS)

Cowen & Co. analyst Phil Nadeau downgraded Nivalis Therapeutics (NASDAQ: NVLS) to Hold today. The company’s shares closed yesterday at $6.25.

According to TipRanks.com, Nadeau is a 3-star analyst with an average return of 1.8% and a 47.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Catabasis Pharmaceuticals, and Voyager Therapeutics Inc.

Nivalis Therapeutics has an analyst consensus of Hold.

Seattle Genetics (NASDAQ: SGEN)

Seattle Genetics (NASDAQ: SGEN) received a Hold rating from Barclays analyst Jonathan Eckard today. The company’s shares closed yesterday at $66.99.

According to TipRanks.com, Eckard is a 1-star analyst with an average return of -4.6% and a 34.8% success rate. Eckard covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Mirati Therapeutics, and Juno Therapeutics.

Seattle Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $53.